Switzerland-based respiratory generics specialist Phargentis has revealed that it has signed an early-stage partnership agreement with a major European generics player for its proposed rival to Chiesi’s Fostair (beclomethasone/formoterol) respiratory brand.
Phargentis Gets European Partner For Fostair Rival
Swiss Respiratory Specialist Previously Developed European Spiriva Generic
Swiss respiratory specialist Phargentis has struck a deal with “one of Europe’s leading generic pharma companies” for commercial rights to its proposed rival to Chiesi’s Fostair (beclomethasone/formoterol) respiratory brand.
More from Deals
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.